HC Wainwright started coverage on shares of Aerie Pharmaceuticals (NASDAQ:AERI) in a research report released on Friday, February 16th, Marketbeat.com reports. The firm issued a buy rating and a $78.00 price objective on the stock.
A number of other analysts have also recently commented on the stock. Guggenheim began coverage on shares of Aerie Pharmaceuticals in a report on Monday, October 23rd. They set a buy rating and a $80.00 target price on the stock. Mizuho reiterated a buy rating and issued a $87.00 price target on shares of Aerie Pharmaceuticals in a research note on Tuesday, December 19th. Canaccord Genuity set a $73.00 target price on shares of Aerie Pharmaceuticals and gave the company a buy rating in a research note on Monday, December 18th. Cantor Fitzgerald set a $77.00 target price on shares of Aerie Pharmaceuticals and gave the company a buy rating in a research note on Monday, December 18th. Finally, BidaskClub raised shares of Aerie Pharmaceuticals from a hold rating to a buy rating in a research report on Tuesday, December 5th. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Aerie Pharmaceuticals has an average rating of Buy and an average target price of $78.75.
Aerie Pharmaceuticals (NASDAQ:AERI) traded down $0.05 during mid-day trading on Friday, hitting $57.90. 261,754 shares of the stock were exchanged, compared to its average volume of 358,982. Aerie Pharmaceuticals has a one year low of $38.14 and a one year high of $66.60. The company has a market capitalization of $2,180.00, a price-to-earnings ratio of -14.19 and a beta of 0.98. The company has a debt-to-equity ratio of 0.91, a current ratio of 10.09 and a quick ratio of 10.09.
A number of institutional investors and hedge funds have recently modified their holdings of AERI. New York State Common Retirement Fund increased its stake in Aerie Pharmaceuticals by 21.4% in the second quarter. New York State Common Retirement Fund now owns 50,224 shares of the company’s stock worth $2,639,000 after purchasing an additional 8,838 shares during the period. UBS Asset Management Americas Inc. increased its stake in Aerie Pharmaceuticals by 38.1% in the second quarter. UBS Asset Management Americas Inc. now owns 17,161 shares of the company’s stock worth $902,000 after purchasing an additional 4,731 shares during the period. GSA Capital Partners LLP purchased a new stake in Aerie Pharmaceuticals in the second quarter worth $258,000. Northern Trust Corp increased its stake in Aerie Pharmaceuticals by 6.6% in the second quarter. Northern Trust Corp now owns 405,116 shares of the company’s stock worth $21,289,000 after purchasing an additional 25,254 shares during the period. Finally, Vanguard Group Inc. increased its stake in Aerie Pharmaceuticals by 55.0% in the second quarter. Vanguard Group Inc. now owns 2,158,825 shares of the company’s stock worth $113,446,000 after purchasing an additional 766,300 shares during the period. Institutional investors own 96.94% of the company’s stock.
WARNING: This story was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://stocknewstimes.com/2018/03/14/aerie-pharmaceuticals-aeri-earns-buy-rating-from-analysts-at-hc-wainwright.html.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.